9th May 2017
A highly successful Metabolomics workshop was hosted by the ACGT and the University of Johannesburg from 6 to 10 March 2017 at the University of Pretoria’s Centre for Bioinformatics and Computational Biology (CBCB). This event built on the first open-source metabolomics workshop, also facilitated by ACGT and UJ in 2016, and is based on the European EMBL course.
A number of European metabolomics experts returned to facilitate the event, and a number of new experts also joined the facilitation team. These included (Europe): Dr Reza Salek (University of Cambridge), Drs Karl Burgess, Naomi Rankin and Justin van der Hooft (University of Glasgow), Dr Jos Hageman (Wageningen University) and Dr Fabien Jourdan (INRA, France). Local trainers included Drs Fidele Tugizimana and Edwin Madala from the University of Johannesburg.
The theme of the workshop was Study Design, Informatics and Statistics and included numerous lectures as well as hands-on data analysis and statistics sessions. An internet-based participatory quiz at the end of each session allowed participants to test their knowledge in a very informal manner, and was received very well by the delegates.
The response to the workshop registration was overwhelming and not all delegates could be accommodated due to space constraints. Those who did take part in the workshop were representative of four of the five ACGT partner institutions and included principal investigators (UP, Wits, UJ) as well as post-graduate researchers (UP, CSIR and UJ).
Feedback received from the delegates was extremely positive. Herewith a few quotations from attendees:
- It provides a week-long introduction to all the core concepts in Metabolomics. Both inexperienced and experienced practitioners of Metabolomics can benefit from attending the course.
- The workshop facilitators were very professional; they also provided a lot of expert knowledge and guidance on metabolic analysis. They provided iterative educational activities and the workshop was wholly enjoyably.
- ACGT deserves a medal for presenting course relevant to staff and students to increase the odds for success.
Metabolomics is a growing field in the partnership and country and following the Pretoria event, the facilitators hosted a shortened version of the workshop in Cape Town, at the University of Cape Town; where they were hosted by Professor Jonathan Blackburn.
Feedback from this event is being utilized to plan a training workshop in the field for 2018. It will in all likelihood be facilitated during the first quarter of 2018. Further news of the event will be circulated in due course.
The Centre would like to thank ThermoFisher and the French Embassy for financial assistance to enable the travel of Drs Karl Burgess, Naomi Rankin and Fabien Jourdan.
The Centre would also like to thank especially Dr Farhahna Allie and Ms Itseng Malao for organizing the workshop; and the facilitators for their time and effort invested in training South African researchers.
9th Mar 2017
The Centre secured a metagenomics expert for a national metagenomics symposium, which was hosted on the 23rd of November 2016. Professor Peter Golyshin (Bangor University, Wales) is a well-known international metagenomics expert and agreed to be the keynote at the national event held at the Department of Science and Technology (DST). A number of national institutions and prominent local researchers were also represented (69 in total), including the Universities of Pretoria, North-West, Cape Town, the Western Cape, VUT, TUT, UNISA, the ARC as well as the CSIR. Research from the CSIR, UP, NWU, UWC as well as UCT was showcased at the event. The symposium ended with a discussion about collaborative opportunities in the field, and it was agreed that the ACGT would make available the research interests, expertise and relevant infrastructure of those in the field of metagenomics on its website.
9th Feb 2017
A detailed three-day open-source proteomics workshop focusing on targeted proteomics and the use of the software package Skyline (this software package can be utilised regardless of hardware utilised in the different institutions and has become highly popular in the proteomics community) was hosted from the 6th to the 8th of December 2016 at the University of the Witwatersrand. The workshop was conducted by Mr Brendan MacLean (who is the chief developer of the software) and Mr Brian Searle (both from the MacCoss lab, Washington University) as well as Dr Birgit Schilling (Gibson lab, Buck Institute). Both institutes are located in the United States. Various advanced topics were covered during the three-day workshop, and delegates from multiple institutions attended. Invitations were also extended to proteomics researchers outside of the region, and researchers hailing from the Universities of Cape Town and Limpopo were also in attendance at the workshop.
12th Jan 2017
Dr Rachel Chikwamba, CSIR Group Executive: Strategic Alliances and Communication, was recently appointed to the African Union (AU) high-level committee on Science, Technology and Innovation Strategy for Africa 2024 (STISA 2024) and to the South African Medical Research Board.
Rachel will join a nine-member High-Level African Panel on Emerging Technologies, which is composed of eminent experts who advise the AU and all its affiliates on harnessing emerging technologies.
In June 2014, the AU adopted a long-term STISA 2024 roadmap to underpin its Agenda 2063, with its main drive as the diversification of sources of economic growth and lifting the continent’s population out of poverty. The strategy aims to foster social and economic transformation by developing human capital, innovation, value addition, industrialisation and entrepreneurship.
STISA 2024 has identified six priority areas namely: Eradicating hunger and ensuring nutrition and food security; prevention and control of diseases and ensuring wellbeing; communication (physical and intellectual mobility); natural resources management and climate change; peace and security and wealth creation. A major recognition in STISA 2024 is that the continent needs to apply existing and emerging technologies to realise the AU vision.
Rachel will also serve on the South African Medical Research Board for the period 2016 to 2019 together with 15 other distinguished leaders.
Story by: Anna Semenya, CSIR News
7th Dec 2016
The ACGT, in conjunction with the CSIR, hosted the 12th Regional Plant Biotechnology Forum on the 8th of September at the CSIR’s International Convention Centre (ICC). The forum focused on “Plant-based biologics” and saw over 50 delegates in attendance.
The forum kicked off with Dr Rachel Chikwamba, CSIR Executive for Strategic Alliances and Communications, giving a brief welcome and introducing the forum’s key-note speaker, Professor Herta Steinkellner. Herta is a professor at the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria. She has expertise in N-glycosylation in plants, recombinant protein production in plants as well as protein glycan engineering. She gave a presentation titled “In planta engineering of post-translational protein modification to enhance biological activity”, which was very well received by the audience and sparked interest in future collaborations between her institution, BOKU, and the CSIR.
Other contributors to the forum included CSIR’s Dr Tsepo Tsekoa and Dr Maretha O’Kennedy, Dr Priyen Pillay from the University of Pretoria and Dr Mauritz Venter from the biotechnology company Azargen. Dr Tsekoa’s presentation was on plant-made antibodies for passive immunisation, while Dr O’Kennedy gave a talk on affordable plant-produced vaccines and biologics through innovative science. Dr Pillay gave a talk on his PhD work, performed at the University of Pretoria, which focused on the contribution of agrofiltration to VP1 recombinant protein degradation. Dr Venter, co-founder and CEO of AzarGen Biotechnologies, gave a talk on “Entrepreneurial endeavours in Plant Biotechnology” and took the audience on a very entertaining journey of how he started his own successful biotechnology company.
The ACGT partner institutions were well represented by the delegates that attended the forum. Delegates were mostly from the ACGT partner institutions (CSIR, UP, ARC and UJ) but also affiliated with the following: Onderstepoort Biological Products (OBP), the Technology Innovation Agency (TIA) and the University of South Africa (UNISA). The forum provided an opportunity for collaborative talks to be initiated between the CSIR, BOKU and Azargen. Potential synergies between these and other research institutions will be evaluated and exploited where possible.
Story by: Thabo Khoza for ACGT
1st Dec 2016
A new study is the first to show that living organisms can be persuaded to make silicon-carbon bonds—something only chemists had done before. Scientists at Caltech “bred” a bacterial protein to have the ability to make the man-made bonds, a finding that has applications in several industries.
Molecules with silicon-carbon, or organosilicon, compounds are found in pharmaceuticals as well as in many other products, including agricultural chemicals, paints, semiconductors, and computer and TV screens. Currently, these products are made synthetically, since the silicon-carbon bonds are not found in nature.
The new research, which recently won Caltech’s Dow Sustainability Innovation Student Challenge Award (SISCA) grand prize, demonstrates that biology can instead be used to manufacture these bonds in ways that are more environmentally friendly and potentially much less expensive.
“We decided to get nature to do what only chemists could do—only better,” says Frances Arnold, Caltech’s Dick and Barbara Dickinson Professor of Chemical Engineering, Bioengineering and Biochemistry, and principal investigator of the new research, published in the Nov. 24 issue of the journal Science.
The study is also the first to show that nature can adapt to incorporate silicon into carbon-based molecules, the building blocks of life. Scientists have long wondered if life on Earth could have evolved to be based on silicon instead of carbon. Science-fiction authors likewise have imagined alien worlds with silicon-based life, like the lumpy Horta creatures portrayed in an episode of the 1960s TV series Star Trek. Carbon and silicon are chemically very similar. They both can form bonds to four atoms simultaneously, making them well suited to form the long chains of molecules found in life, such as proteins and DNA.
“No living organism is known to put silicon-carbon bonds together, even though silicon is so abundant, all around us, in rocks and all over the beach,” says Jennifer Kan, a postdoctoral scholar in Arnold’s lab and lead author of the new study. Silicon is the second most abundant element in Earth’s crust.
The researchers used a method called directed evolution, pioneered by Arnold in the early 1990s, in which new and better enzymes are created in labs by artificial selection, similar to the way that breeders modify corn, cows, or cats. Enzymes are a class of proteins that catalyze, or facilitate, chemical reactions. The directed evolution process begins with an enzyme that scientists want to enhance. The DNA coding for the enzyme is mutated in more-or-less random ways, and the resulting enzymes are tested for a desired trait. The top-performing enzyme is then mutated again, and the process is repeated until an enzyme that performs much better than the original is created.
Directed evolution has been used for years to make enzymes for household products, like detergents; and for “green” sustainable routes to making pharmaceuticals, agricultural chemicals, and fuels.
In the new study, the goal was not just to improve an enzyme’s biological function but to actually persuade it to do something that it had not done before. The researchers’ first step was to find a suitable candidate, an enzyme showing potential for making the silicon-carbon bonds.
“It’s like breeding a racehorse,” says Arnold, who is also the director of the Donna and Benjamin M. Rosen Bioengineering Center at Caltech. “A good breeder recognizes the inherent ability of a horse to become a racer and has to bring that out in successive generations. We just do it with proteins.”
The ideal candidate turned out to be a protein from a bacterium that grows in hot springs in Iceland. That protein, called cytochrome c, normally shuttles electrons to other proteins, but the researchers found that it also happens to act like an enzyme to create silicon-carbon bonds at low levels. The scientists then mutated the DNA coding for that protein within a region that specifies an iron-containing portion of the protein thought to be responsible for its silicon-carbon bond-forming activity. Next, they tested these mutant enzymes for their ability to make organosilicon compounds better than the original.
After only three rounds, they had created an enzyme that can selectively make silicon-carbon bonds 15 times more efficiently than the best catalyst invented by chemists. Furthermore, the enzyme is highly selective, which means that it makes fewer unwanted byproducts that have to be chemically separated out.
“This iron-based, genetically encoded catalyst is nontoxic, cheaper, and easier to modify compared to other catalysts used in chemical synthesis,” says Kan. “The new reaction can also be done at room temperature and in water.”
The synthetic process for making silicon-carbon bonds often uses precious metals and toxic solvents, and requires extra processing to remove unwanted byproducts, all of which add to the cost of making these compounds.
As to the question of whether life can evolve to use silicon on its own, Arnold says that is up to nature. “This study shows how quickly nature can adapt to new challenges,” she says. “The DNA-encoded catalytic machinery of the cell can rapidly learn to promote new chemical reactions when we provide new reagents and the appropriate incentive in the form of artificial selection. Nature could have done this herself if she cared to.”
The Science paper, titled “Directed Evolution of Cytochrome c for Carbon-Silicon Bond Formation: Bringing Silicon to Life,” is also authored by Russell Lewis and Kai Chen of Caltech. The research is funded by the National Science Foundation, the Caltech Innovation Initiative program, and the Jacobs Institute for Molecular Engineering for Medicine at Caltech.
Story by: Whitney Clavin for Caltech
16th Nov 2016
The developing world is achieving significant growth in a broad cross-section of biotechnology fields, many of them directly tied to food production, health and other dimensions of human well-being, says a new analysis commissioned by the CAS-TWAS Centre of Excellence in Biotechnolgy.
The first-of-its kind report, ‘Biotechnology in Developing Countries: Growth and Competitiveness’ was released today by the Beijing-based centre, which is organized by the Chinese Academy of Sciences (CAS), and The World Academy of Sciences (TWAS). The CAS-TWAS Centre of Excellence for Biotechnology report provides an assessment of research and patents in the field across the global South.
“This report is, to the best of my knowledge, the first extensive document summarizing the development status of a specific technology area in the developing world,” writes Bai Chunli, the president of both CAS and TWAS, in the foreword. “It provides a strong, valuable assessment of biotechnology activities in developing countries, as measured in scientific publications and patents.”
Simultaneously, it highlights the important role of international collaboration in the rapid pace of growth in the field, especially in sub-Saharan Africa.
The report found that from 2004 to 2015:
- Biotechnology research has grown steadily, with a 117% increase in published studies. However, biotechnology research from the developing world is less cited in other research papers – only about 83% as much.
- Over 85% of the biotech papers that were co-authored by science-and-technology lagging countries resulted from international collaborations. Countries in sub-Saharan Africa in particular benefited from international collaboration, resulting in a notably high impact.
- Patent filings in the developing world have been most active in industry, food and environmental biotechnology sectors. Most of those patents have been new enzymes, totalling 79,694 – comprising of more than 40% of the overall patents.
- China leads in biotechnology papers produced in the ten-year period with 78,263, followed by India with 24,081 and Brazil with 17,769. It also leads all countries with 149,339 patent families, followed by India with 15,420 and Mexico with 14,574
As a critical driver of science that boosts food resources, improves nutritional health, and battles environmental pollution, biotechnology is one of the most productive research fields of our time. The report broadly surveys research and development work in biotechnology carried out from 2005 to 2014.
Bai said the report could be valuable to governments and policymakers, as well as related research sectors, industry sectors and international bodies. He added that CAS and TWAS hope the report will help to nurture a flourishing biotechnology sector in all developing countries and regions.
“Embracing the great opportunities of the emerging bio-economy, developing countries need to sharpen their awareness, increase their commitment and gradually build their own strength in the dynamic fields of biotechnology,” he writes in a foreword to the report. “Only in that way can they fully exploit its potential to drive economic growth and social development.”
The report also includes other findings: And East Asia, Southeast Asia and the Pacific Region had a particularly strong increase in biotechnology papers. That region also put out the most patents. Within biotechnology, it found, the most published field of research was infectious diseases.
The report is available online.
Story by: Sean Treacy for TWAS.ORG
2nd Nov 2016
A team of scientists at Royal Botanical Gardens Kew has embarked on the mammoth task of creating a single database of the world’s medicinal plant species.
Our knowledge of beneficial botany is dispersed across many sources, and is complicated with most species having a variety of different names.
The team at Kew says its work will help pharmacists and regulators, as well as relevant scientific research.
To date, the resource covers an estimated 18,000 different species.
“From those 18,000 species of plant, we have something like 90,000 different names that are used within the health community and by regulators,” explained Bob Allkin from Kew’s Medicinal Plant Name Services project (MPNS).
“They use many different names for the same plant; some of the names are ambiguous, and we have 230,000 scientific names for those plants.”
What’s in a name?
He described why there was a need to compile a single reference for the increasingly globalised plant-based medicinal market.
“Pharmacists have traditionally referred to products in great detail, about how it should be prepared. They would also suggest what plant, and what bit of the plant, it can be derived from, such as just the root or just the leaves,” Dr Allkin told BBC News.
“However, from a botanical point of view, they have been rather loose about how they referred to the plants; they would have used common names, or they would have used pharmaceutical names.
“In both cases, those names are used differently in different places. Obviously, language is an issue but even within the English-speaking world, one common name can be used in different ways to mean different plants. This leads to ambiguity.”
When you are dealing with medicine, ambiguity can result in unacceptable consequences.
In a high profile incident, more than 100 people in Belgium suffered kidney failure as a result of taking weight-loss pills. Unfortunately, a number of the casualties lost their lives as a result of taking the pills.
“The reason for this was because one substance was substituted for another because they had a similar name. This shows that there are very serious consequences to not being precise about what plants are being used,” Dr Allkin warned.
“We are compiling all of the names of the plants as used in herbal medicinal products, as used in [various editions of] pharmacopeia and medical literature. They use a mix of common names, in different languages, they also use what are known as pharmaceutical names – which in many cases are also written in Latin – and they also use scientific names. They use a whole mix of things.”
There are numerous pharmacopeia (books containing technical instructions to identify compound medicines) – such as the Chinese, Japanese, and European editions – as well as databases used by regulators, such as the US Food and Drug Administration.
Dr Allkin observed: “We then map those names as used by the regulators and health profession to Kew Garden’s comprehensive and authoritative global plant taxonomies.”
He said that in order for regulators to be able to accurately identify what plants are being used, it is necessary to use scientific names.
“That is the only way because those scientific names are referred to a physical reference in a herbarium store, such as the one at Kew, and those physical specimens tie down what that [scientific] name refers to, as well as its chemical components and DNA etc,” he explained.
“The problem for people who are not botanists is that there are various obstacles to using the scientific names properly. In the past, botanists have provided wonderful online resources that are useful to other botanists, but not necessarily intelligible to those working in the health sector.”
However, this presents a problem of its own. Dr Allkin acknowledge that one of the challenges of using scientific nomenclature is that there are many more names than there are plants.
It is estimated that there are between 360,000 and 400,000 species of flowering plants in the world, yet there are 1.6 million scientific names for plants known to science.
“Each plant often has multiple scientific names; this is particularly true of useful plants like medicinal plants because they have been well studies and well described, therefore end up having lot of different or alternative names,” Dr Allkin said.
“We know of one plant in the British pharmacopeia that has more than 500 scientific synonyms.
“One consequence of that is that it makes it very hard to find all the research that has been published about that plant, as research might have been published under any one of many names.”
Dr Allkin said that if someone searched for details of previous research of a plant using just one of its names then you – on average – would find about 10% to 15% of the previous reach, meaning you would not find up to 85% of previous scientific work on the plant.
Another problem is that names keep changing – there are 10,000 changes to scientific nomenclature each year.
“This is because there are new plants being found, there are about 2,000 of those, and then there are about 4,000 cases each year when a plant is moved from one genus into another genus,” he added.
“This is done because the molecular or chemical data that becomes available makes us realise that that particular species is much more closely related in another genus rather than the one it current belongs to.
“Our project is about making Kew’s botanical expertise accessible to all.”
Story by:BBC Newsfor
17th Oct 2016
For the past 18 years, the L’Ore’al-UNESCO for Women in Science (http://www.ForWomenInScience.com) programme has encouraged, promoted and honoured female scientists all over the world. More than 2,500 researchers from 112 countries have been distinguished for their extraordinary discoveries and supported at key moments in their careers.
Dr Stephanie Fanucchi, senior researcher at the Biomedical Translational Research Initiative (BTRI) – an initiative of the CSIR and the University of Cape Town, funded by the Department of Science and Technology was a recipient of the L’Ore’al-UNESCO Sub-Saharan Africa 2016 postdoctoral fellowship of 10 000 euros.
Her research uses cutting edge microscopes and synthetic biology tools to understand how immune genes are regulated. The title of her project is deciphering the roles of non-coding RNAs in immune gene regulation, which she will conduct in Prof. Musa Mhlanga’s laboratory, BTRI technical manager.
“Aberrant gene regulation underpins a multitude of disease states, including autoimmune disease and cancer. Yet, despite this, our understanding of the intricacies of gene regulation remains poorly understood'” says Fanucchi. “Therefore, a detailed understanding of immune gene regulation will have far-reaching implications with respect to our understanding and treatment of cancer, chronic diseases such as diabetes, allergy responses and a host of other diseases and important cellular processes.”
The prestigious ceremony where fellows were presented with the award took place on 28 September at The Venue Greenpark, Johannesburg.
Story by Tendani Tsedu for CSIR Media relations, October 2016
30th Sep 2016
In early September, the ACGT teamed up with WITS and UP’s 2016 iGem team to sponsor and host a 2-day informative workshop and symposium on Synthetic Biology. Synthetic biology is a multidisciplinary field of science that involves the design and construction of novel artificial biomolecular components, pathways or networks in organisms or the redesign of existing natural biological systems. Although still in its infancy, Synthetic biology is rapidly expanding and has shown huge potential and benefit in a diverse number of applications, including the development of cheaper drugs, the treatment of antibiotic resistant infections, genetic disorders, therapies to treat diseases such as cancer, biofuel production.
The 2-day event was well attended and included participants from the CSIR, ARC, UP, WITS and the Department of Environmental Affairs. The workshop was interactive and delegates had the opportunity to hear about and discuss some of activities and approaches in the field that are currently being explored in South America, UK and South Africa. On the first day, a workshop was facilitated by Dr. Fernán Federici, assistant professor at the Pontifical Catholic University of Chile and a research fellow at the University of Cambridge. Dr. Federici introduced open source technologies for science, education and bioengineering as well as started open discussions about how to implement new collaborative frameworks in Africa and Latin America. Dr. Geoffrey Baldwin, a Reader in Biochemistry in the Department of Life Sciences and Centre for Synthetic Biology and Innovation (CSynBI) at Imperial College London, also presented on his work on the BASIC method for standard DNA assembly approaches.
On the second day, delegates were treated to a keynote address by Dr. Baldwin titled: “Engineering Biology in the Genomic Age: the Synthetic Biology Revolution” as well a presentation by the 2016 UP iGEM team on their WattsAptamer project, where they described the design of “Synthetic laccases and DNA aptamers for thylakoid tethering in photo-electrochemical cells”.
These two events provided an informative platform for an exchange of ideas and interdisciplinary discussions as well as the potential for new collaborations. The ACGT is committed to supporting and hosting events that benefit Biotechnology and the Bioscience Community, particularly our partners, so for more information on upcoming workshops, symposia and bioinformatics training events, visit the events page on the ACGT website (www.acgt.co.za), like us on Facebook (http://www.facebook.com/ACGT.biotec) or contact Farhahna Allie at
* Thank you to Whitehead Scientific for sponsorship towards these events